Efficacy and safety of Glecaprevir/Pibrentasvir in patients with severe renal impairment in Japan: a prospective, multicenter study (KTK 49 Liver Study Group)

Conference Reports for NATAP

The International Liver Congress™
EASL - European Association for the
Study of the Liver
2019 April 10-14
Vienna Austria


Efficacy and safety of Glecaprevir/Pibrentasvir in patients with severe renal impairment in Japan: a prospective, multicenter study (KTK 49 Liver Study Group)

	Reported by Jules Levin EASL 2019 April 10-14 Vienna